207 related articles for article (PubMed ID: 30120157)
21. Impact of guideline changes on use or omission of radiation in the elderly with early breast cancer: practice patterns at National Comprehensive Cancer Network institutions.
McCormick B; Ottesen RA; Hughes ME; Javid SH; Khan SA; Mortimer J; Niland JC; Weeks JC; Edge SB
J Am Coll Surg; 2014 Oct; 219(4):796-802. PubMed ID: 25127504
[TBL] [Abstract][Full Text] [Related]
22. Comorbidity burden and guideline-concordant care for breast cancer.
Kimmick G; Fleming ST; Sabatino SA; Wu XC; Hwang W; Wilson JF; Lund MJ; Cress R; Anderson RT;
J Am Geriatr Soc; 2014 Mar; 62(3):482-8. PubMed ID: 24512124
[TBL] [Abstract][Full Text] [Related]
23. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
[TBL] [Abstract][Full Text] [Related]
24. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
[TBL] [Abstract][Full Text] [Related]
25. ReCAP: Treatment Patterns and Cost of Care Associated With Initial Therapy Among Patients Diagnosed With Operable Early-Stage Human Epidermal Growth Factor Receptor 2-Overexpressed Breast Cancer in the United States: A Real-World Retrospective Study.
DaCosta Byfield S; Buck PO; Blauer-Peterson C; Poston SA; DaCosta Byfield S; Buck PO; Blauer-Peterson C; Poston SA
J Oncol Pract; 2016 Feb; 12(2):159-67. PubMed ID: 26395563
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.
Blank PR; Filipits M; Dubsky P; Gutzwiller F; Lux MP; Brase JC; Weber KE; Rudas M; Greil R; Loibl S; Szucs TD; Kronenwett R; Schwenkglenks M; Gnant M
Pharmacoeconomics; 2015 Feb; 33(2):179-90. PubMed ID: 25404424
[TBL] [Abstract][Full Text] [Related]
28. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
[TBL] [Abstract][Full Text] [Related]
29. Influence of Age on Guideline-Concordant Cancer Care for Elderly Patients in the United States.
Fang P; He W; Gomez DR; Hoffman KE; Smith BD; Giordano SH; Jagsi R; Smith GL
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):748-757. PubMed ID: 28366580
[TBL] [Abstract][Full Text] [Related]
30. Changes over time in the impact of gene-expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study.
Kuijer A; Drukker CA; Elias SG; Smorenburg CH; Th Rutgers EJ; Siesling S; van Dalen T
Int J Cancer; 2016 Aug; 139(4):769-75. PubMed ID: 27062369
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer treatment guidelines in older women.
Giordano SH; Hortobagyi GN; Kau SW; Theriault RL; Bondy ML
J Clin Oncol; 2005 Feb; 23(4):783-91. PubMed ID: 15681522
[TBL] [Abstract][Full Text] [Related]
32. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
33. Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe.
Jerusalem G; Neven P; Marinsek N; Zhang J; Degun R; Benelli G; Saletan S; Ricci JF; Andre F
BMC Cancer; 2015 Oct; 15():787. PubMed ID: 26498283
[TBL] [Abstract][Full Text] [Related]
34. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
[TBL] [Abstract][Full Text] [Related]
35. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
[TBL] [Abstract][Full Text] [Related]
36. Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol.
Krzyzanowska MK; Julian JA; Powis M; Howell D; Earle CC; Enright KA; Mittmann N; Trudeau ME; Grunfeld E
BMC Cancer; 2019 Sep; 19(1):884. PubMed ID: 31488084
[TBL] [Abstract][Full Text] [Related]
37. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
38. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
Gandhi S; Fletcher GG; Eisen A; Mates M; Freedman OC; Dent SF; Trudeau ME
Curr Oncol; 2015 Mar; 22(Suppl 1):S82-94. PubMed ID: 25848343
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
